Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report - Poll - MDSpire

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

  • By

  • Fu-Yi Wang

  • Li-Long Zhu

  • Cheng Ji

  • Jie Deng

  • Lu Han

  • Fei Song

  • Zhong Chen

  • June 2, 2026

  • 0 min

Share

Original Source(s)

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

  • by Fu-Yi Wang, Li-Long Zhu, Cheng Ji, Jie Deng, Lu Han, Fei Song, Zhong Chen

  • June 2, 2026

Related Content

The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival